---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-069212"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:59:13.608417+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Erasca receives FDA Fast Track Designation for naporafenib combo in NRAS-mutant melanoma

## Summary
- FDA granted Fast Track Designation to naporafenib + trametinib for unresectable/metastatic NRASm melanoma after PD-(L)1 failure.
- FTD facilitates development and expedites review for drugs addressing unmet medical needs.
- Benefits include more frequent FDA interactions and potential rolling submission of marketing application.
- Naporafenib (ERAS-007) is an oral pan-RAF inhibitor; trametinib is a MEK inhibitor already marketed as MEKINIST.

## SEC filing metadata
- accession: 0000950170-23-069212
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017023069212/0000950170-23-069212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017023069212/eras-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-069212
- JSON: https://secwatch.observer/filing/0000950170-23-069212.json
- Plain text: https://secwatch.observer/filing/0000950170-23-069212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.